Christopher Washbourne
University of East Anglia
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Christopher Washbourne.
Journal of Nutritional Biochemistry | 2017
Jonathan Tang; Holly Nicholls; Isabelle Piec; Christopher Washbourne; John Dutton; Sarah Jackson; Julie P. Greeves; William D. Fraser
24,25(OH)2D is the product of 25(OH)D catabolism by CYP24A1. The measurement of serum 24,25(OH)2D concentration may serve as an indicator of vitamin D catabolic status and the relative ratio with 25(OH)D can be used to identify patients with inactivating mutations in CYP24A1. We describe a LC-MS/MS method to determine: (1) the relationships between serum 24,25(OH)2D and 25(OH)D; (2) serum reference intervals in healthy individuals; (3) the diagnostic accuracy of 24,25(OH)2D measurement as an indicator for vitamin D status; 4) 24,25(OH)2D cut-off value for clinically significant change between inadequate and sufficient 25(OH)D status. Serum samples of healthy participants (n=1996) from Army recruits and patients (n=294) were analysed. The LC-MS/MS assay satisfied industry standards for method validation. We found a positive, concentration-dependent relationship between serum 24,25(OH)2D and 25(OH)2D concentrations. The 25(OH)D:24,25(OH)2D ratio was significantly higher (P<.001) at 25(OH)D<50 nmol/L. The reference interval for 25(OH)D:24,25(OH)2D ratio in healthy subjects was 7-23. Measurement of serum 24,25(OH)2D can be used as predictor of vitamin D status, a concentration of>4.2 nmol/L was identified as a diagnostic cut-off for 25(OH)D replete status. One patient sample with an elevated 25(OH)D:24,25(OH)2D ratio of 32 and hypercalcaemia who on genetic testing confirmed to have a biallelic mutation of CYP24A1. Our study demonstrated the feasibility of a combined 24,25(OH)2D and 25(OH)D assessment profile. Our established cut-off value for 24,25(OH)2D and ratio reference ranges can be useful to clinicians in the investigation of patients with an impaired calcium/phosphate metabolism and may point towards the existence of CYP24A1 gene abnormalities.
Calcified Tissue International | 2016
Isabelle Piec; Christopher Washbourne; Jonathan Tang; Emily Fisher; Julie P. Greeves; Sarah Jackson; William D. Fraser
Clinical Mass Spectrometry | 2016
Jonathan Tang; John Dutton; Isabelle Piec; Darrell Green; Emily Fisher; Christopher Washbourne; William D. Fraser
Bone Abstracts | 2016
Jonathan Tang; Holly Nicholls; John Dutton; Isabelle Piec; Christopher Washbourne; Lanja Saleh; A Novak; Graeme L. Close; Helen M. Macdonald; Sarah Jackson; Julie P. Greeves; William D. Fraser
Archive | 2017
Isabelle Piec; John Dutton; Sulaiman Al Riyami; Christopher Washbourne; Inez Schoenmakers; Hillel Galitzer; Gregory Burshtein; Philip Schwartz; Jonathan Tang; William D. Fraser
Archive | 2017
Jonathan Tang; Holly Nicholls; Nicole Ball; John Dutton; Isabelle Piec; James Rudge; Christopher Washbourne; William D. Fraser
Archive | 2017
Sulaiman Al Riyami; Jonathan Tang; John Dutton; Christopher Washbourne; Hillel Galitzer; William D. Fraser
Society for Endocrinology BES 2016 | 2016
Isabelle Piec; Allison Chipchase; Holly Nicholls; Jonathan Tang; Christopher Washbourne; William Fraser
Society for Endocrinology BES 2016 | 2016
Jonathan Tang; Holly Nicholls; John Dutton; Isabelle Piec; Christopher Washbourne; Lanja Saleh; A Novak; Graeme L. Close; Helen M. Macdonald; William Fraser
Archive | 2016
Isabelle Piec; Holly Nicholls; Jonathan Tang; Christopher Washbourne; William D. Fraser